Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 4/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18322201 | 0.84 | THRB (0.50) | ALDH1A1BRD4CYP26A1CYP24A1HPGD | |
| SCHEMBL28615795 | 0.84 | THRB (0.50) | ALDH1A1BRD4CYP26A1CYP24A1HPGD | |
| SCHEMBL18322205 | 0.83 | NR1H4 (0.47) | RAB9AMTNR1AHPGDNQO2MTNR1B | |
| SCHEMBL20241344 | 0.83 | NR1H4 (0.47) | RAB9AMTNR1AHPGDNQO2MTNR1B | |
| SCHEMBL20241215 | 0.81 | BRD4 (0.43) | NPC1RAB9ABRD4CYP26A1CYP24A1 | |
| SCHEMBL28620218 | 0.81 | CYP26A1 (0.43) | ALDH1A1BRD4CYP26A1CYP24A1MTNR1A | |
| SCHEMBL29405817 | 0.79 | APP (0.45) | RAB9ATDP1ALDH1A1HPGD | |
| SCHEMBL28619079 | 0.79 | APP (0.45) | RAB9ATDP1ALDH1A1HPGD | |
| SCHEMBL5206057 | 0.75 | MAOB (0.42) | NPC1RAB9ABRD4CYP26A1CYP24A1 | |
| SCHEMBL31377731 | 0.72 | GRM2 (0.36) | BRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766878-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3555082-B1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
| CN-108137557-B | Nrf2 modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3766878-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3555068-B1 | 3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3307729-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109648-A1 | 3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016203401-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272095-B2 | NRF2 regulators | NFE2L2, KEAP1, NQO1 | NPC1 316/4885RAB9A 2711/4885TDP1 4360/4885 |
| US-20190224212-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | NPC1 316/4885RAB9A 2711/4885TDP1 4360/4885 |
| US-20180169110-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | NPC1 316/4885RAB9A 2711/4885TDP1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.